7th National Formulary India 2026 Launched: Key Facts for Government Exams

7th National Formulary India 2026 launched by Anupriya Patel with 653 drugs, 34 chapters and 20 appendices. Know key facts for government exams.

7th National Formulary of India 2026 Launched to Promote Safe and Rational Medicine Use

The 7th edition of the National Formulary of India (NFI) 2026 was launched in New Delhi on 21 September 2026 by Union Minister of State for Health and Family Welfare and Chemicals and Fertilisers, Anupriya Patel. The launch took place during the 6th National Pharmacovigilance Week programme organised by the Indian Pharmacopoeia Commission (IPC) at the Dr Ambedkar International Centre. The updated formulary has also been made available digitally through the NFI Online platform.

What Is the National Formulary of India?

The National Formulary of India is an important reference and guidance document for healthcare professionals. It aims to promote the appropriate, rational and safe use of medicines in clinical practice. The publication helps healthcare professionals make informed decisions regarding prescribing and administering medicines and serves as a link between scientific standards and practical healthcare delivery.

Key Features of NFI 2026

The 2026 edition contains 34 chapters, 20 appendices and 653 drugs. These include 42 fixed-dose combinations and 30 immunologicals. Drug monographs have also been revised to bring them in line with the National List of Essential Medicines and various National Health Programmes. These updates are intended to provide healthcare professionals with current guidance for safer and evidence-based medicine use.

Digital Access to the Updated Formulary

Alongside the printed publication, NFI 2026 is available digitally through NFI Online. The digital version provides links to important healthcare resources, including National Health Programmes, immunisation schedules, Jan Aushadhi information and guidance on the safe disposal of unused or expired pharmaceutical products. This digital approach can improve access to updated medicine-related information for healthcare professionals and students.

Launch Linked with National Pharmacovigilance Week

The launch coincided with the 6th National Pharmacovigilance Week, observed from 17 to 23 September 2026. The theme of the week was “Promoting Rational Use of Medicines through Pharmacovigilance: A Step Towards Safer Healthcare.” The programme brought together government officials, regulators, healthcare professionals, researchers, academicians and other stakeholders involved in medicine safety and patient care.

New Measures to Strengthen Patient Safety

The government also introduced additional measures alongside NFI 2026. These included a guidance document for hospitals on safety monitoring and reporting of adverse events related to medical devices and the ADR-PvPI 2.0 mobile application for iOS users. These initiatives are designed to strengthen the reporting and monitoring of safety concerns associated with medicines and medical devices.

Biovigilance Programme of India Approved

A significant development announced during the programme was the approval of the Biovigilance Programme of India. Under this programme, the Indian Pharmacopoeia Commission will lead efforts to strengthen the reporting, assessment, monitoring and prevention of adverse events associated with medicines and biological products used in organ and tissue transplantation. This expands India’s patient-safety monitoring framework beyond medicines and medical devices.

Role of Pharmacovigilance in Healthcare

Pharmacovigilance involves the systematic collection, assessment and analysis of information related to adverse drug reactions. In India, the Pharmacovigilance Programme of India is coordinated through the National Coordination Centre at the Indian Pharmacopoeia Commission. The Materiovigilance Programme of India complements this system by monitoring adverse events associated with medical devices.

Importance for Government Exam Aspirants

The launch of NFI 2026 is important for aspirants preparing for UPSC, State PSC, SSC, banking, railway, defence, teaching and other government examinations. Questions can be framed around the National Formulary of India, Indian Pharmacopoeia Commission, pharmacovigilance, National List of Essential Medicines, National Pharmacovigilance Week and the newly approved Biovigilance Programme. Remembering the edition number, launch date, contents and responsible institution can be particularly useful for current-affairs and general-science sections.

Why This News Is Important

Strengthening Rational Use of Medicines

The 7th National Formulary of India is important because it provides updated guidance for the rational and safe use of medicines. Rational medicine use helps ensure that patients receive appropriate medicines in the correct manner while maintaining attention to safety and effectiveness. NFI 2026 therefore connects scientific knowledge with practical healthcare decision-making.

Expansion of Patient-Safety Monitoring

The development is significant because the government has simultaneously expanded its safety-monitoring approach through pharmacovigilance, materiovigilance and biovigilance. The approval of the Biovigilance Programme introduces a dedicated framework for monitoring adverse events associated with medicines and biological products used in organ and tissue transplantation.

Digital Transformation in Healthcare

The availability of NFI 2026 through the NFI Online platform represents an important step towards easier access to updated medicine-related information. Digital access also provides links to immunisation schedules, National Health Programmes, Jan Aushadhi resources and information on safe pharmaceutical-waste disposal.

Relevance for Competitive Examinations

For government-exam aspirants, this development connects several important subjects, including public health, pharmaceuticals, science and technology, government institutions and healthcare regulation. The launch date, edition number, number of chapters, appendices and drugs, as well as the role of the Indian Pharmacopoeia Commission, are potential factual areas for examination questions.

Historical Context: National Formulary of India and Pharmacovigilance in India

Origin of the National Formulary of India

The National Formulary of India has a long history as a reference resource for medicines. The first edition was published in 1960. According to available background information, the publication has subsequently been revised and updated to reflect developments in medicine, healthcare programmes and pharmaceutical standards.

Role of the Indian Pharmacopoeia Commission

The Indian Pharmacopoeia Commission is associated with the development and publication of the National Formulary of India. The IPC functions under the Ministry of Health and Family Welfare and plays an important role in maintaining standards relating to medicines and strengthening medicine-safety systems. The NFI has been published periodically by the IPC in its modern series since 2009.

Development of Pharmacovigilance in India

India has progressively strengthened systems for identifying and assessing adverse reactions to medicines. The Pharmacovigilance Programme of India provides a national mechanism for collecting and analysing adverse drug reaction information. The Materiovigilance Programme subsequently broadened safety monitoring to medical devices. The newly approved Biovigilance Programme extends the framework further to biological products associated with organ and tissue transplantation.

Previous Edition and NFI 2026

The 6th edition preceded the 2026 edition, while the new edition updates medicine-related information and aligns drug monographs with the National List of Essential Medicines and National Health Programmes. NFI 2026 therefore represents another stage in the continuing development of India’s national reference framework for rational and safe medicine use.

Key Takeaways from 7th National Formulary of India 2026

Frequently Asked Questions

1. What is the National Formulary of India 2026?

The National Formulary of India (NFI) 2026 is the 7th edition of a guidance document for healthcare professionals. It aims to promote the rational, safe and evidence-based use of medicines.

2. Who launched the 7th National Formulary of India 2026?

Anupriya Patel, Union Minister of State for Health and Family Welfare and Chemicals & Fertilisers, launched the 7th edition on 21 September 2026 in New Delhi.

3. Which organisation publishes the National Formulary of India?

The Indian Pharmacopoeia Commission (IPC) publishes the National Formulary of India periodically.

4. When was the first edition of the National Formulary of India published?

The first edition was published in 1960. The NFI has been published periodically by IPC since 2009 in its modern series.

5. How many chapters are included in NFI 2026?

The 2026 edition contains 34 chapters and 20 appendices.

6. How many drugs are covered in NFI 2026?

NFI 2026 contains information on 653 drugs, including 42 fixed-dose combinations and 30 immunologicals.

7. With which important list have the drug monographs in NFI 2026 been aligned?

The drug monographs have been revised to align with the National List of Essential Medicines (NLEM) and National Health Programmes.

8. What is the theme of the 6th National Pharmacovigilance Week 2026?

The theme is “Promoting Rational Use of Medicines through Pharmacovigilance: A Step Towards Safer Healthcare.” The week is being observed from 17 to 23 September 2026.

9. What is the Biovigilance Programme of India?

The Biovigilance Programme of India is a newly approved patient-safety initiative under which the IPC will lead efforts to report, assess, monitor and prevent adverse events associated with medicines and biological products used in organ and tissue transplantation, including products administered to donors and recipients.

Some Important Current Affairs Links